Motor Neurone Disease (MND) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025

Motor Neurone Disease (MND) Emerging Therapy and TPP Insights

Thelansis’s “Motor Neurone Disease (MND) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Motor Neurone Disease (MND) Overview

Motor neurone disease is a progressive neurological condition in which the nerve cells that control voluntary muscle movement gradually deteriorate. As these neurons are lost, muscles weaken and shrink, leading to increasing difficulty with walking, speaking, swallowing, and eventually breathing. The disease usually begins subtly but advances relentlessly, with most patients facing a shortened life expectancy of only a few years after diagnosis. While the exact cause is not fully understood, both genetic mutations and abnormal cellular processes are thought to contribute. There is no cure, and current treatments—such as riluzole and edaravone—offer only modest benefits. Multidisciplinary care, including physiotherapy, nutritional support, and respiratory management, plays a central role in maintaining quality of life. The severity of the condition and the lack of effective therapies highlight the urgent need for new approaches, including gene‑targeted treatments and neuroprotective strategies, making MND a major focus of ongoing research in neurology.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Read more: Motor Neurone Disease (MND) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025